Shares of Danaher Co. (NYSE:DHR) have been given a consensus recommendation of “Buy” by the sixteen brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $321.53.
A number of equities research analysts have issued reports on the company. Zacks Investment Research upgraded Danaher from a “hold” rating to a “strong-buy” rating and set a $334.00 target price on the stock in a research note on Wednesday, July 28th. Cowen raised their target price on Danaher from $275.00 to $350.00 and gave the company an “outperform” rating in a research note on Friday, July 23rd. Credit Suisse Group raised their target price on Danaher from $306.00 to $370.00 and gave the company an “outperform” rating in a research note on Friday, September 10th. Bank of America raised their target price on Danaher from $340.00 to $360.00 and gave the company a “buy” rating in a research note on Friday, September 10th. Finally, The Goldman Sachs Group lifted their price objective on shares of Danaher from $280.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, July 23rd.
In other Danaher news, CAO Robert S. Lutz sold 5,000 shares of Danaher stock in a transaction dated Friday, August 13th. The stock was sold at an average price of $313.40, for a total transaction of $1,567,000.00. Following the transaction, the chief accounting officer now owns 21,155 shares of the company’s stock, valued at approximately $6,629,977. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joakim Weidemanis sold 6,700 shares of Danaher stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $298.93, for a total value of $2,002,831.00. Following the transaction, the executive vice president now directly owns 70,720 shares in the company, valued at approximately $21,140,329.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 52,477 shares of company stock worth $15,439,958. 11.40% of the stock is owned by corporate insiders.
Danaher stock opened at $295.86 on Monday. The company has a market cap of $211.21 billion, a PE ratio of 39.40, a P/E/G ratio of 1.93 and a beta of 0.70. The company has a fifty day moving average price of $316.49 and a two-hundred day moving average price of $278.87. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.26 and a quick ratio of 1.88. Danaher has a 12 month low of $211.22 and a 12 month high of $333.96.
Danaher (NYSE:DHR) last posted its earnings results on Thursday, July 22nd. The conglomerate reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.05 by $0.41. The company had revenue of $7.22 billion for the quarter, compared to analysts’ expectations of $6.71 billion. Danaher had a return on equity of 17.68% and a net margin of 21.00%. The firm’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period last year, the business posted $1.44 earnings per share. Equities research analysts anticipate that Danaher will post 9.49 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, October 29th. Investors of record on Thursday, September 30th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend is Wednesday, September 29th. Danaher’s payout ratio is currently 13.31%.
Danaher Company Profile
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines.
Recommended Story: Intrinsic Value
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.